A new cancer immunotherapy drug showed promising results in an early-stage clinical trial, controlling disease in nearly 60% of patients with advanced tumors that had resisted previous treatments.
Mass General Brigham Cancer Institute researchers co-led the first-in-human trial of invikafusp, which selectively activates immune cells and delivers a potent immunotherapy molecule.